| |
|
|
|
TBA, Philadelphia,PA
2/19/2009 to 2/20/2009
The Conference will provide an extensive look at the successes as well as the challenges that face modern cancer drug development and provide an update on cancer drugs currently in development through clinical trials. A look at novel compounds and emerging targets will prime attendees with the future direction of cancer drugs with key topics to be discussed by leading experts including mTOR inhibitors, angiogenesis, PI3K inhibitors, rapamycin analogs, PARP inhibitors, VEGF Receptor inhibitors, and much more. The new frontier of combination therapeutics and therapies will be also covered in detail. Sign up now as space is limited!
|
|
|
|
|
|
|
|
|
Organized by:
|
|
GTCbio |
|
|
Invited Speakers:
|
|
Beverly Packard
President
OncoImmunin, Inc.
Kunwar Shailubhai
CSO
Synergy Pharmaceuticals, Inc
Domagoj Vucic
Scientist, Protein Engineering
Genentech
George Blumenschein
MD Anderson Cancer Center
Daniel Powell
Deputy Director Cell & Vaccine Production Facility
University of Pennsylvania
Dinah Sah
Senior Director, Research
Alnylam Pharmaceuticals
Guillerno Morales
Director, Chemistry
Semafore Pharmaceuticals
John Martens
Senior Scientist, Department of Medical Oncology
Erasmus Medical Center
Nathalie Scholler
Assistant Professor
University of Pennsylvania
Jeffery Schlom
Chief, Laboratory of Tumor Immunology and Biology
NIH/NCI
Xuesong Liu
Principle Investigator
Abbott Laboratories
Anne Ree
Professor of Oncology
University of Oslo, Norwegian Radium Hospital
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
1/19/2009
|
|
|
|
|
|
|
|
Registration:
|
|
https://gtcbio.com/userpart/user_registration.aspx?Str=143
|
|
|
E-mail:
|
|
jason.yi@gtcbio.com
|
|
|
|
|
|
|
|
|